Park Square is pleased to announce the placement of Brian Hotchkiss as Chief Business Officer at Bexorg, Inc. A spinout of Nenad Sestan’s lab at Yale University, Bexorg has developed the world’s first whole-brain perfusion model. Through this, the company generates unprecedented insight into neural function and opens new avenues for developing therapies for brain diseases.  

Hotchkiss is a seasoned business development and strategy executive whose background spans leading pharmaceutical companies and entrepreneurial biotechs. Most recently, he served as Chief Business Officer at Protego Biopharma. Prior, he spent nearly seven years progressing through roles of increasing responsibility at Stealth BioTherapeutics. There he was instrumental in shaping the corporate strategy and driving several transactions, including a transformative collaboration with Alexion.  Earlier in his career, Hotchkiss held senior business development roles at Ember Therapeutics and Pfizer.  

Hotchkiss received his M.S. in Biology at Brown University and his M.B.A from the University of Virginia Darden School of Business. He also received his M.S. in Chemical Engineering at the University of Iowa and his B.S. in Chemical Engineering at Cornell University.